Rate this app:

More details

Add your questions or answers

Q: How to get the best score?

Q: What is your favourite trick in this game/app?

Q: What is your strategy?

NBN C&A Gameplay, Trailers and Related Videos

Watch C&A Landscape Service LLC video.

Watch Spontan Kauf/ Haul // Hollister, Kiko, Levis - Sinchen video.

Watch catalogo das camisas onix nova marca linha estampadas super estilosas APROVEITE!! video.

Watch Makeup Look | Alltagslook Urban Decay Nude by Nature Loréal MAC | Mamacobeauty video.

Watch Ponta Grossa em respeito a diversidade video.

Watch COMPRINHAS ACUMULADAS: LOJAS MARISA, RIACHUELO, AMERICANAS, BOANA E MAIS. video.

Watch Video Corporativo para la CAM y Telefónica video.

Watch La navidad de Guido (Cierre Cine de Salón 2012) video.

Watch бесплатные смс.mp4 video.

About the application:

The NbN was developed because it has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it appropriately inform the clinician about neuroscience-based prescribing. Very often we prescribe “antidepressants” for “anxiety” disorders or “second generation antipsychotics” to unhappy patients. This practice is confusing. • The mission of NbN is to embed our current neuroscience advances in the nomenclature. • The scope is to contain all medications with CNS indications and to harness this fresh nomenclature to assist clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. This proposed nomenclature aims to reflect the current pharmacology knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled this apk should have taken the stand that our current knowledge base is not enough to define the exact pharmacological domain or the correct mechanisms of action. However, as a taskforce, we feel that it’s better to show a cutting-edge scientific interpretation than to wait for the definitive conclusion. After all, we need to treat our patients now, and we cannot postpone treatment until all the facts are known. Therefore this nomenclature is based on:- 1. The need to treat now 2. Updated neuroscience insights 3. The judgment of the members of the taskforce 4. The assumption that kids are developing and therefore developmental aspects (e.g. liver and kidney function, brain developmental scene) must be considered in use and dosage. Along these lines, we have come up with a nomenclature that is driven by: pharmacology and mode of action. The NbN reflects current knowledge and understanding regarding neurotransmitters / molecules / systems being modified + mode / mechanism of action 4 clinically relevant dimensions are also included: 1.Approved indications – Based on the suggestions of major regulatory bodies (e.g. FDA, EMA, etc.) for this age group. 2. Efficacy and side effects – Aimed to highlight situations in which a compound has no formal approval for an indication, yet there is evidence to help its use in extra indication(s), for example well supported expert rules. In the side effects section, only serious, life-changing or prevalent side-effects are listed. 3. “Practical notes” – Summarizes the clinical knowledge that has been "filtered" though the taskforce "sieve". 4. Neurobiology – Derived from empirical data. For those who would like to know more about the pharmacology there is a direct link to the relevant website of IUPHAR – our collaborator in this endeavor. As this is an on-going process, we recognize that there are going to be omissions. Based on your feedback, another colleagues’ responses (the “wisdom of clinicians”), fresh reports and fresh findings, appropriate updates will be undertaken. NbN C&A embeds current neuroscience advances in order to provide a comprehensive and coherent naming system for kids and adolescence. The taskforce hopes that it will assist clinicians to create informed decisions in their "psychopharmacological steps" and that it clarifies the rationale for prescribing.